ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Shortages of HIV meds?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 175483" data-attributes="member: 3"><p>Hey Jerry</p><p></p><p>We have not heard of any shortages in my poz network. Can you ask to be switched to an integrase regimen, or this new non-nuke that is not showing fat gains?</p><p></p><p>[URL unfurl="true"]https://www.merckconnect.com/doravirine/dosing-administration/?gclid=EAIaIQobChMIsqX-5InU6AIVTf7jBx1eZgAdEAAYASAAEgL6ZPD_BwE&gclsrc=aw.ds[/URL]</p><p></p><p>"Weight Gain and ART</p><p>Large cohorts, followed by analyses of randomized controlled trials, have demonstrated fairly consistent risk factors for excessive weight gain on ART including female sex, black race, older age, and first-line therapy vs suppressed switch. Integrase inhibitors, particularly second-generation dolutegravir (DTG) and bictegravir, and tenofovir alafenamide (TAF) have been most associated with weight gain, whereas tenofovir disoproxil fumarate (TDF) appears relatively protective. Similarly, the lower rates of weight gain in first-line trials of the NNRTI doravirine make it an obvious candidate for scrutiny. "</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 175483, member: 3"] Hey Jerry We have not heard of any shortages in my poz network. Can you ask to be switched to an integrase regimen, or this new non-nuke that is not showing fat gains? [URL unfurl="true"]https://www.merckconnect.com/doravirine/dosing-administration/?gclid=EAIaIQobChMIsqX-5InU6AIVTf7jBx1eZgAdEAAYASAAEgL6ZPD_BwE&gclsrc=aw.ds[/URL] "Weight Gain and ART Large cohorts, followed by analyses of randomized controlled trials, have demonstrated fairly consistent risk factors for excessive weight gain on ART including female sex, black race, older age, and first-line therapy vs suppressed switch. Integrase inhibitors, particularly second-generation dolutegravir (DTG) and bictegravir, and tenofovir alafenamide (TAF) have been most associated with weight gain, whereas tenofovir disoproxil fumarate (TDF) appears relatively protective. Similarly, the lower rates of weight gain in first-line trials of the NNRTI doravirine make it an obvious candidate for scrutiny. " [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Shortages of HIV meds?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top